QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NYSE:BMY

Bristol-Myers Squibb - BMY Price Target & Analyst Ratings

$72.77
+1.54 (+2.16%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$69.80
$72.88
50-Day Range
$71.01
$81.13
52-Week Range
$62.90
$81.43
Volume
12.97 million shs
Average Volume
8.57 million shs
Market Capitalization
$154.72 billion
P/E Ratio
23.70
Dividend Yield
3.14%
Price Target
$80.60

Bristol-Myers Squibb Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$80.60
10.76% Upside
High Prediction$95.00
Average Prediction$80.60
Low Prediction$60.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$80.60$79.57$78.85$66.00
Predicted Upside10.76% Upside7.76% Upside7.36% Upside10.52% Upside
Get Bristol-Myers Squibb Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.


BMY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bristol-Myers Squibb Stock vs. The Competition

TypeBristol-Myers SquibbMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.65
2.46
Consensus RatingHoldBuyHold
Predicted Upside13.15% Upside1,299.12% Upside8.18% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/17/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Brayer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00+31.02%
1/3/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$70.00 ➝ $78.00+7.17%
11/17/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$78.00+1.00%
11/10/2022Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$85.00 ➝ $88.00+10.30%
10/27/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight$61.00 ➝ $60.00-19.41%
10/12/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$69.00 ➝ $66.00-5.24%
10/10/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
9/27/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$85.00+21.17%
9/14/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$82.00 ➝ $76.00+6.98%
9/12/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$92.00 ➝ $94.00+33.98%
7/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $85.00+13.62%
7/27/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$73.00-2.32%
6/6/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geoff Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$78.00 ➝ $80.00+6.43%
6/3/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Baum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$90.00+19.73%
6/3/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/2/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$76.00 ➝ $81.00+7.61%
11/1/2021Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$49.00-16.10%
11/30/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$73.00 ➝ $77.00+23.56%
11/16/2020Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$76.00+19.46%
11/10/2020Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform$72.00+12.36%
11/6/2020Gabelli
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/26/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$70.00+21.00%
6/1/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BMY Price Target - Frequently Asked Questions

What is Bristol-Myers Squibb's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Bristol-Myers Squibb stock is Hold based on the current 1 sell rating, 6 hold ratings and 7 buy ratings for BMY. The average twelve-month price prediction for Bristol-Myers Squibb is $80.60 with a high price target of $95.00 and a low price target of $60.00. Learn more on BMY's analyst rating history.

Do Wall Street analysts like Bristol-Myers Squibb more than its competitors?

Analysts like Bristol-Myers Squibb less than other Medical companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for medical companies is Buy. Learn more on how BMY compares to other companies.

Does Bristol-Myers Squibb's stock price have much upside?

According to analysts, Bristol-Myers Squibb's stock has a predicted upside of 9.30% based on their 12-month price targets.

What analysts cover Bristol-Myers Squibb?

Bristol-Myers Squibb has been rated by Atlantic Securities, Cantor Fitzgerald, Credit Suisse Group, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:BMY) was last updated on 2/2/2023 by MarketBeat.com Staff